Search Results

Univercells to test proprietary mRNA vaccine delivered with Altamira’s SemaPhore™ nanoparticles Targeting safer and accessible mRNA vaccines Altamira Therapeutics Ltd.

Gamma Biosciences announced that its operating company, Univercells Technologies, a leading provider of novel biomanufacturing technologies for flexible and scalable advanced therapies and vaccine production, has been acquired by Donaldson Company, Inc..

Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, and Univercells S.A., a global life sciences company using bioprocessing expertise and next-generation technologies to open access to bioproduction, today announced a research collaboration agreement on an undisclosed

Italian ReiThera Srl., German LEUKOCARE AG, and Belgian Univercells S.A., announced a strategic collaboration for the development and large-scale manufacturing of a novel adenoviral vector-based vaccine against COVID-19.

Univercells SA (‘Univercells’) and Global Health Investment Fund (‘GHIF’) are pleased to announce the closing of a €16 million ($18.8 million) Series B equity financing. Investment proceeds will support the continued development of Univercells’ game-changing biomanufacturing technology, which has the potential to dramatically reduce the capital expenditure, physical footprint and operating costs required to produce a variety of complex biologics

The proceeds will support the commercial roll-out of its viral platform and the completion of its recombinant platform.

This funding will enable the company to launch a program aimed at developing its innovative protein platform, paving the way for the cost-effective production of biosimilars.